Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell transplantation (ASCT). Thus, improving efficacy of HDCT in MM remains an unresolved issue. This randomized phase II trial compared standard 200 mg/m(2) Mel HD...

Descripción completa

Detalles Bibliográficos
Autores principales: Farag, Sarah, Bacher, Ulrike, Jeker, Barbara, Legros, Myriam, Rhyner, Gaelle, Lüthi, Jean-Marc, Schardt, Julian, Zander, Thilo, Daskalakis, Michael, Mansouri, Behrouz, Manz, Chantal, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018972/
https://www.ncbi.nlm.nih.gov/pubmed/35444232
http://dx.doi.org/10.1038/s41409-022-01681-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018972/
https://www.ncbi.nlm.nih.gov/pubmed/35444232
http://dx.doi.org/10.1038/s41409-022-01681-y

Ejemplares similares